KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Intangibles (2016 - 2025)

Gsk has reported Intangibles over the past 11 years, most recently at $22.3 billion for Q4 2025.

  • For Q4 2025, Intangibles rose 11.87% year-over-year to $22.3 billion; the TTM value through Dec 2025 reached $22.3 billion, up 11.87%, while the annual FY2025 figure was $22.3 billion, 11.87% up from the prior year.
  • Intangibles for Q4 2025 was $22.3 billion at Gsk, up from $19.9 billion in the prior quarter.
  • Over five years, Intangibles peaked at $40.5 billion in Q4 2021 and troughed at $16.8 billion in Q4 2022.
  • A 5-year average of $23.8 billion and a median of $21.1 billion in 2024 define the central range for Intangibles.
  • Biggest five-year swings in Intangibles: crashed 58.58% in 2022 and later grew 11.87% in 2025.
  • Year by year, Intangibles stood at $40.5 billion in 2021, then crashed by 58.58% to $16.8 billion in 2022, then rose by 9.14% to $18.3 billion in 2023, then grew by 8.64% to $19.9 billion in 2024, then grew by 11.87% to $22.3 billion in 2025.
  • Business Quant data shows Intangibles for GSK at $22.3 billion in Q4 2025, $19.9 billion in Q4 2024, and $18.3 billion in Q4 2023.